Initial Public Offering
Baird served as a co-manager on this offering
AboutBeiGene, Ltd. (“BeiGene” or the “Company”) (NASDAQ-GS: BGNE) recently completed an initial public offering of 7,590,000 American Depositary Shares (“ADSs”), each representing 13 ordinary shares, at a price of $24.00 per ADS, generating gross proceeds of approximately $182.2 million. The Company intends to use the net proceeds from the offering to develop drug candidates and for working capital and other general corporate purposes.
BeiGene is a global, clinical-stage, research-based biotechnology company focused on targeted and immuno-oncological therapeutics. With a team of 215+ scientists and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and a lasting impact on cancer patients. BeiGene is headquartered in Beijing, China.
For additional information about this transaction, please contact:
- February 2016
- BeiGene, Ltd.
- Target Location